Michael Melnick is a biotech scientist, investor and entrepreneur. Dr. Melnick started his career as a Staff Scientist at the pioneering biotech company New England Biolabs, then helped found the cancer research and diagnostics company Cell Signaling Technology where he was VP of Business and Corporate Development. He was a Venture Partner at CMEA Capital where he invested in life science, industrial biotech, and cleantech, and has served in operating roles at various biotech companies including most recently BioAtla (NASDAQ: BCAB). He has a B.S. with honors and M.S. in Biological Sciences from Stanford University, and a Ph.D. in Genetics from Harvard University.